Literature DB >> 32296514

Long-term stability of ready-to-use norepinephrine solution at 0.2 and 0.5 mg/mL.

Sixtine Gilliot1, Morgane Masse1, Stéphanie Genay1, Damien Lannoy1, Christine Barthélémy1, Bertrand Décaudin1, Pascal Odou1.   

Abstract

Objectives: Norepinephrine is a vasopressor frequently administered after dilution to treat hypotension and shocks in intensive care units. The stability of norepinephrine is known to be highly sensitive to storage conditions. Moreover, medication errors linked to the dilution step are frequent and may be deleterious for critically-ill patients, especially in intensive care units. This study aimed to evaluate the stability of ready-to-use diluted norepinephrine solutions prepared at two target concentrations (0.2 and 0.5 mg/mL), according to the summary of product characteristics, and stored for 365 days in two containers: AT-closed cyclic olefin copolymer vials, and polypropylene syringes.
Methods: A fast reversed-phase liquid chromatography method coupled with an ultra-violet detector was developed to assess the chemical stability of norepinephrine solutions. Validation was conducted according to the linearity of the calibration ranges, selectivity, sensitivity, accuracy and precision. Dosage, sub-visible particle contamination, pH monitoring and sterility assays were performed. Chemical stability was maintained if the measured concentration respected the lower limit of 90% of the initial concentration. Containers were stored at -20±5°C, +5±3°C and +25±2°C with 60±5% relative humidity in a dark closed enclosure.
Results: Stability was successfully maintained for every concentration and container tested when stored at -20±5°C and +5±3°C. In these storage conditions, particle contamination, pH monitoring and sterility assay respected the required criteria. Chemical degradation and colouring of solutions appeared before the end of the 1 year study period for most norepinephrine solutions stored at room temperature. Conclusions: Ready-to-use solutions containing 0.2 and 0.5 mg/mL norepinephrine in polypropylene syringes or cyclic olefin copolymer vials must be stored at refrigerated or frozen temperatures to obtain acceptable 1 year shelf-stability. Exposure to higher temperatures significantly decreases shelf-stability. Our study protocol for compounding polypropylene syringes and cyclic olefin copolymer vials containing norepinephrine is adapted to implementation in centralised intravenous additive services. © European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  IV administration; drug stability; intensive & critical care; shelf life; validation analytical procedure

Mesh:

Substances:

Year:  2020        PMID: 32296514      PMCID: PMC7147565          DOI: 10.1136/ejhpharm-2019-002146

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  16 in total

1.  Kinetics of degradation in solution of epinephrine by molecular oxygen.

Authors:  T D SOKOLOSKI; T HIGUCHI
Journal:  J Pharm Sci       Date:  1962-02       Impact factor: 3.534

2.  Physicochemical stability of norepinephrine bitartrate in polypropylene syringes at high concentrations for intensive care units.

Authors:  E D'Huart; J Vigneron; I Clarot; B Demore
Journal:  Ann Pharm Fr       Date:  2019-02-22

3.  Stability of 10 mg/mL cefuroxime solution for intracameral injection in commonly used polypropylene syringes and new ready-to-use cyclic olefin copolymer sterile vials using the LC-UV stability-indicating method.

Authors:  Frédéric Feutry; Nicolas Simon; Stéphanie Genay; Damien Lannoy; Christine Barthélémy; Bertrand Décaudin; Pierre Labalette; Pascal Odou
Journal:  Drug Dev Ind Pharm       Date:  2015-05-26       Impact factor: 3.225

Review 4.  Centralized intravenous additive services (CIVAS): the state of the art in 2010.

Authors:  J-D Hecq
Journal:  Ann Pharm Fr       Date:  2010-12-30

5.  Stability of high-concentration dopamine hydrochloride, norepinephrine bitartrate, epinephrine hydrochloride, and nitroglycerin in 5% dextrose injection.

Authors:  T E Peddicord; K M Olsen; T L ZumBrunnen; D J Warner; L Webb
Journal:  Am J Health Syst Pharm       Date:  1997-06-15       Impact factor: 2.637

6.  Accuracy of preparation of i.v. medication syringes for anesthesiology.

Authors:  Cyril Stucki; Anna-Maria Sautter; Adriana Wolff; Sandrine Fleury-Souverain; Pascal Bonnabry
Journal:  Am J Health Syst Pharm       Date:  2013-01-15       Impact factor: 2.637

7.  Photocatalytic actions of the pesticide metabolite 2-hydroxyquinoxaline: destruction of antioxidant vitamins and biogenic amines - implications of organic redox cycling.

Authors:  Andreas Behrends; Rüdiger Hardeland; Heiko Ness; Sascha Grube; Burkhard Poeggeler; Chandana Haldar
Journal:  Redox Rep       Date:  2004       Impact factor: 4.412

8.  Stability of five catecholamines and terbutaline sulfate in 5% dextrose injection in the absence and presence of aminophylline.

Authors:  D W Newton; E Y Fung; D A Williams
Journal:  Am J Hosp Pharm       Date:  1981-09

9.  Stability of norepinephrine infusions prepared in dextrose and normal saline solutions.

Authors:  Maryse Tremblay; Martin R Lessard; Claude A Trépanier; Pierre C Nicole; Linda Nadeau; Gilles Turcotte
Journal:  Can J Anaesth       Date:  2008-03       Impact factor: 5.063

Review 10.  Systematic evidence review of rates and burden of harm of intravenous admixture drug preparation errors in healthcare settings.

Authors:  Nancy Hedlund; Idal Beer; Torsten Hoppe-Tichy; Patricia Trbovich
Journal:  BMJ Open       Date:  2017-12-28       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.